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Abstract
Background
We examined the real-world effectiveness of ART as an HIV prevention tool among HIV ser-
odiscordant couples in a programmatic setting in a low-income country.
Methods
We enrolled individuals from HIV serodiscordant couples aged18 years of age in Jinja,
Uganda from June 2009 – June 2011. In one group of couples the HIV positive partner was
receiving ART as they met clinical eligibility criteria (a CD4 cell count250 cells/ μL or
WHO Stage III/IV disease). In the second group the infected partner was not yet ART-
eligible. We measured HIV incidence by testing the uninfected partner every three months.
We conducted genetic linkage studies to determine the source of new infections in serocon-
verting participants.
Results
A total of 586 couples were enrolled of which 249 (42%) of the HIV positive participants
were receiving ART at enrollment, and an additional 99 (17%) initiated ART during the
study. The median duration of follow-up was 1.5 years. We found 9 new infections among
partners of participants who had been receiving ART for at least three months and 8 new
infections in partners of participants who had not received ART or received it for less than
three months, for incidence rates of 2.09 per 100 person-years (PYRs) and 2.30 per 100
PYRs, respectively. The incidence rate ratio for ART-use was 0.91 (95% confidence interval
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0.31-2.70; p=0.999). The hazard ratio for HIV seroconversion associated with ART-use by
the positive partner was 1.07 (95% CI 0.41-2.80). A total of 5/7 (71%) of the transmissions
on ART and 6/7 (86%) of those not on ART were genetically linked.
Conclusion
Overall HIV incidence was low in comparison to previous studies of serodiscordant couples.
However, ART-use was not associated with a reduced risk of HIV transmission in this study.
Introduction
Antiretroviral therapy (ART) has been shown to dramatically reduce plasma viral load (VL) in
HIV-infected individuals. Studies conducted prior to the widespread introduction of ART in
Uganda demonstrated that the HIV VL of the infected partner is the primary determinant of
HIV transmission among serodiscordant couples [1] This and other studies led to research
examining the effects that HIV treatment has contributed to reducing the spread of HIV in
industrialized countries with large comprehensive, treatment programs[2, 3]. The HPTN 052
study confirmed, in a randomized trial, that the initiation of early ART is associated with a
96% reduction in HIV transmission between serodiscordant couples, many of whom were
recruited in low and middle-income countries[4]. This research has led to further speculation
that expansion of HIV treatment in sub-Saharan Africa may eventually lead to similar reduc-
tions in HIV transmission as observed in high-income countries [5]. Recently reported empiri-
cal evidence from South Africa appears to support this assertion [6].
However, the context of highly-resourced randomized trials and ecologic studies from
industrialized countries is very different from that of ART programs in low-income countries,
where the majority of HIV-infected individuals accessing treatment reside. In such programs
support for adherence to therapy, transportation, nutrition and other ancillary services are
often lacking. As well, human resources [7, 8] and clinical service infrastructure [9] to support
ART delivery are also often limited. Therefore, there may be challenges in extrapolating the
results of previous research to the realities of how and where most HIV-infected individuals
receive care and treatment in resource-limited settings.
We conducted an observational study to examine the effectiveness of ART as prevention in
a large HIV care and treatment program in rural Uganda in order to determine the real-world
effectiveness of HIV treatment as prevention among serodiscordant couples.
Methods
We conducted a prospective cohort study of co-habiting HIV serodiscordant couples of indi-
viduals aged18 years of age known as the Highly Active Antiretroviral therapy as Prevention
(HAARP) study. All HIV-infected participants were clients of The AIDS Support Organization
(TASO), in Jinja, Uganda. Participants were eligible if they reported at least two episodes of
sexual intercourse in the previous three months. Prior to enrollment, the HIV negative partner
must have undergone an HIV test and received the results. Both the positive and negative par-
ticipants were required to have already disclosed their HIV serostatus to their partner. The
TASO clinic in Jinja provides care to over 8000 HIV infected individuals with over 5000 receiv-
ing ART. The ART program began in 2004 and is financed through the US Presidents Emer-
gency Fund for AIDS Relief.
ART and HIV Prevention in Serodiscordant Couples
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Study participants provided informed written consent to their participation. Prior to study
enrollment a research assistant read aloud the consent form in the preferred, of one of three
local languages and responded to all questions raised by potential recruits. If the individual
agreed to study participation, they then signed the form (either with a signature, or with a
thumb-print for individuals who could not write). The study, including the consent forms and
data collection tools, received scientific and ethics approval from the Institutional Review
Boards of the Uganda Virus Research Institute and the Uganda National Council for Science
and Technology in Uganda and the University of British Columbia in Vancouver, Canada.
In one group of couples the HIV positive partner was receiving ART because of meeting the
clinical or laboratory eligibility requirements in effect at the time of the study; a CD4 cell count
250 cells/ μL or WHO Stage III or IV disease[10]. In the second group of couples, the infected
partner was not yet ART-eligible. Both groups received couple-based HIV transmission risk-
reduction counseling and condoms on a quarterly basis. Clinical and behavioral data were col-
lected every six months and the HIV-infected participants received their routine care through
TASO clinicians every one to three months. Routine VL testing is not available for TASO cli-
ents, but clinical monitoring and CD4 cell count testing are conducted every six months to
monitor ART effectiveness in accordance with the Ugandan guidelines.
HIV incidence in the two groups was measured by testing the uninfected partner every
three months using two different point of care tests, applied in a serial algorithm (Determine,
Alere Medical Co Ltd; StatPak, Chembio Diagnostic Systems Inc.). In the event of discordant
results between the first and second tests, a third test (UniGold, Trinity Biotech Manufacturing
Ltd.) was used to make the final diagnosis. All new HIV diagnoses were also subsequently con-
firmed by a laboratory-based ELISA test. The study was powered to detect a 75% reduction in
HIV incidence associated with ART-use assuming that HIV incidence in the couples with
untreated HIV would be 4 per 100 person years with an α of 0.05 and a power of 0.8, using a
two-sided test.
For individuals who initiated ART near enrollment or during the study, observation time
was considered to be not on ART until three months after the individual first started receiving
ART. Once these individuals had received ART for three months, all subsequent observation
time was considered to be while receiving ART. We collected sociodemographic and beha-
vioural data through questionnaires administered by research assistants at enrollment and
every six months thereafter. We also conducted clinical assessments at the same intervals and
collected vaginal swabs for bacterial vaginosis and performed rapid diagnostic tests for syphilis
(Determine, Inverness Medical, UK), every six months. Treatment for other sexually transmit-
ted infections was based on syndromic management in accordance with local guidelines.
We collected and stored plasma and serum samples every six months for viral load testing
(COBAS Ampliprep/TaqMan HIV-1 test V2.0 (Roche, Mannheim, Germany)) and herpes
simplex type 2 (HSV2) antibody testing (Kalon HSV2 IgG ELISA, Guilford, UK) at the end of
the study. In couples where HIV seroconversion occurred, we conducted VL testing on all sam-
ples from the HIV positive participant during the study and for non-seroconverting couples,
we tested only the sample drawn at the last study visit. We conducted HSV2 serology on all
study participants using the enrollment sample and again on those individuals who were HSV2
negative at enrollment on the last samples drawn. HIV sequencing was conducted on plasma
samples drawn from the HIV positive participant and their partners who seroconverted where
the VL measured was300 copies/ mL using an in house method. For seroconverting couples
where we could not obtain sufficient virus in plasma samples for genotyping, we drew addi-
tional whole blood samples to extract proviral DNA from intact CD4 cells.
Briefly, RT-PCR followed by nested PCR of the 5’ region of the pol gene generated a 1341
base-pair fragment. We analyzed Protease (PR aa 1–99) and Reverse Transcriptase (RT aa
ART and HIV Prevention in Serodiscordant Couples
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1–320) regions of the pol gene (fragment length 1341 base-pairs). This fragment was purified,
sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Inter-
national, Foster City, CA), and analysed on an ABI Prism 3130 Genetic Analyser (Applied Bio-
systems International). All resulting sequences were genotyped using SCUEAL [11]. In order
to conduct a phylogenetic analysis with appropriate community controls, all Ugandan HIV pol
sequences with dates were downloaded from the Los Alamos National Laboratory Database
(HXB2 positions 2253 to 3549, min length 600 bases). A sequence similarity search (ViroBlast)
[12]was performed on each subtype dataset separately to retrieve the ten closest sequences to
each of the study sequences within the LANL Ugandan dataset. Phylogenetic trees for subtypes
A1, D and A1D recombinants were reconstructed using Bayesian Evolutionary Analysis by
Sampling Trees (BEAST)[13]. Analyses were run in duplicate under a Skyride model with a
gamma distributed uncorrelated lognormal molecular clock and SRD06 substitution model,
for 100,000,000 generations. Convergence was assessed in Tracer and duplicate runs were com-
bined. Maximum clade credibility (MCC) trees for genetic distance and time were summarized
with Tree Annotator. For each couple pair, we generated Time to Most Recent Common
Ancestors and pairwise genetic distances fromMCC trees.
We conducted Kruskal Wallis and Chi-squared tests to compare couples where the HIV
positive participant did not receive ART, with those where the positive participant was receiv-
ing ART from enrollment and couples where the positive participant began ART during the
study. We also conducted bivariate analyses comparing couples where seroconversion occurred
during follow-up with those where seroconversion did not occur. We calculated the incidence
rate ratio for HIV seroconversion using exact Poisson regression and used univariate Cox pro-
portional hazards modeling to examine the hazard associated with time-to-seroconversion in
the HIV negative participants, with ART exposure of the HIV positive participant used as a
time-updated variable. Given the small number of transmission events we observed, we were
unable to develop multivariate models, rather we conducted several stratified Cox proportional
hazard analyses[14] to account for different baseline hazard function for each of several poten-
tial confounders. These analyses stratified participants based on: 1) the circumcision status the
male participants, 2) the HSV2 serostatus of the HIV infected participant 3) the HSV2 serosta-
tus of the HIV uninfected participant, 4) the gender of the HIV-infected partner and 5) the
recorded CD4 cell count nadir of the HIV positive participant. All analyses were conducted
using SAS Version 9.3 (SAS Corporation, Cary, North Carolina).
Results
A total of 586 couples were enrolled between June 1, 2009 and June 20, 2011. In 249(42.5%) of
these couples, the HIV-infected participant was receiving ART at enrollment and in 99 (17%)
couples the HIV positive participant initiated ART during the study. In the remaining 238
(40.6%) couples the HIV-infected participant did not receive ART during the study. The
median duration of ART-use for those on ART at enrollment was 2.3 years. Table 1 shows the
comparison of these three groups of participants. The gender distribution of the HIV-infected
partner was somewhat uneven through the three groups, but these differences were not statisti-
cally significant (p = 0.074). We found a lower proportion of circumcised male partners among
the couples receiving ART at enrollment (34% vs.45% vs. 43%), but these differences were only
marginally statistically significant (p = 0.053). There were no differences in terms of proportion
of participants in polygyneous relationships, intergenerational partnerships, number of chil-
dren or other sociodemographic variables.
Couples where the positive participant was receiving ART at enrollment were more likely to
report always using condoms in the past three months in comparison to those who initiated
ART and HIV Prevention in Serodiscordant Couples
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during the study or were never on ART (67% vs. 62% vs.58% respectively; p = 0.003). They also
reported longer relationships with their primary sexual partner than non-ART couples
(median 12 vs. 10 years; p = 0.018), but not longer than couples who started ART during the
study (median 12 years). There were no differences between the three groups in terms of con-
dom use at last sex, pregnancy intentions, alcohol use, number of non-spousal sexual partners
or other behavioural characteristics.
There were also differences in clinical characteristics between the three groups (Table 2).
The HIV positive partners in the couples receiving ART at enrollment or began during the
study were more likely to be HSV2 seropositive (91% and 92%, respectively) in comparison to
those who were never on ART during the study (84%) (p = 0.050). There were no differences
in the use of injectable contraception, genital ulcer disease or bacterial vaginosis across the
groups.
Follow-up of study participants continued until December 14, 2011 when the median dura-
tion of study participation was 1.5 years. A total of 42 couples did not return for the first
follow-up visit, such that 544 couples were able to be assessed for an outcome (Fig 1). We
found 9 new infections among partners of participants who had been receiving ART for at least
three months and 8 new infections in partners of participants who had not received ART or
Table 1. Characteristics of individuals in 586 discordant couples enrolled in the HAARP Study.
Never on ART
during the study
Began ART
during the study
On ART at
enrollment
P- value
N (%) 238 (41%) 99 (17%) 249 (42%)
Gender of HIV positive participant Male (%) 121 (51%) 60 (61%) 150 (60%) 0.074
Female (%) 117 (49%) 39 (39%) 99 (40%)
Age of male partner Median (IQR) 40 (34–47) 41 (36–50) 43 (37–50) 0.002
Age of female partner Median (IQR) 33 (29–40) 36 (30–40) 36 (30–40) 0.002
Intergenerational partnership (>10 yrs age difference
between male and female partner)
83 (35%) 29 (29%) 90 (36%) 0.472
*Primary Language Spoken (male response) Lusoga 164 (69%) 63 (65%) 144 (60%) 0.095
Other 72(31%) 34 (35%) 96 (40%)
Polygyneous partnership (%) 58 (24%) 26 (26%) 61 (25%) 0.928
Male partner circumcised (%) 102 (43%) 44 (45%) 83 (34%) 0.053
Used a condom at last sex (%) (positive partner) 159 (67%) 68 (69%) 188 (76%) 0.095
Used a condom at last sex (%) (negative partner) 164 (69%) 69 (70%) 192 (77%) 0.101
Condom use in the last 3 months (male response) Always 138 (58%) 61 (62%) 167 (67%) 0.003
Sometimes 51 (21%) 15 (15%) 58 (23%)
Never 49 (21%) 23 (23%) 24 (10%)
Age of sexual debut (female) Median (IQR) 16 (15–18) 16 (15–18) 16 (15–18) 0.191
# of lifetime sex partners (male) Median (IQR) 6 (4–12) 6 (4–10) 7 (4–13) 0.315
# of lifetime sex partners (female) Median (IQR) 3 (2–4) 3 (2–4) 3 (2–4) 0.573
Male sexual decision making (male) 90 (38%) 35 (36%) 87 (35%) 0.819
Duration (years) of relationship with primary partner
(positive partner with partner 1) Median (IQR)
10 (5–18) 12 (6–22) 12 (6–21) 0.018
Number of sexual partners for non-polygynous males More than
one
9 (5%) 5 (7%) 9 (5%) 0.786
One 171 (95%) 68 (93%) 179 (95%)
>1 sexual partner reported by female 4 (2%) 1 (1%) 3 (1%) 0.896
Intend to have more children (male response) 88 (41%) 34 (38%) 77 (35%) 0.401
Intend to have more children (female response) 51 (26%) 25 (30%) 47 (24%) 0.605
doi:10.1371/journal.pone.0132182.t001
ART and HIV Prevention in Serodiscordant Couples
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received it for less than three months, for incidence rates of 2.09 per 100 person-years (PYRs)
and 2.30 per 100 PYRs, respectively. The incidence rate ratio was 0.91 (95% confidence interval
[CI] 0.31–2.70; p = 0.999) associated with ART-use by the positive partner. Among the 99 cou-
ples where the positive partner began ART during the study, the incidence rate was 2.56 per
100 PYRs for the time observed on ART and 4.54 per 100 PYRs for the observation time not on
ART, for an IRR of 0.56 (95%CI: 0.10–3.08; p = 0.804). A total of 3/8 ART participants and 8/8
of the non-ART participants had VLs>1000 copies/ mL either immediately prior to- or just
after seroconversion. One of the ART participants did not have a measured VL result during
the study. We were able to determine partial viral pol gene sequence from both partner viruses
in 14 of the 17 seroconverter couples. Of these 79% (11/14) were found to be genetically linked;
5/7(71%) in the ART arm and 6/ 7(86%) in the non-ART arm. Linked infections were always
supported by posterior probabilities of 1. Mean pairwise genetic distance among couples was
0.02 nucleotide substitutions per site, and median 0.015.
Table 3 shows the characteristics of the couples where the HIV positive participant was
receiving ART prior to seroconversion of their partner. Note that only three of the HIV positive
individuals who were receiving ART whose partners seroconverted had VLs>1000 copies/ mL,
although for one ART participant, we were missing VL results. One of these three self-reported
clear non-adherence to therapy, was found to have a VL of>300,000 and did not consistently
use condoms. Another individual initiated treatment just over three months prior to his part-
ner’s seroconversion and had a previous VL off treatment was>250,000 copies/ mL, but a VL
taken on the day of his partner’s first positive test of 176 copies/ mL. For all other seroconver-
sions occurring among couples where the positive partner was receiving ART, the measured
Table 2. Clinical characteristics of study participants.
Never on ART
during the study
Began ART
during the study
On ART at
enrollment
P- value
CD4 cell count at enrollment of HIV positive partner
Median (IQR)
515 (389–684) 248 (156–366) 392 (240–539) <0.001
Median VL (log 10 copies/ mL) at study exit or prior to
sero-conversion
4.4 (3.5–4.9) 1.4 (1.3–2.7) 1.3 (1.3–1.5) <0.001
VL >1000 copies/ mL at study exit or prior to
seroconversion*
140/177 (79%) 23/98 (23.%) 16/216 (7%) <0.001
HSV2 serology of HIV negative partner HSV2 positive at
enrollment
183 (77%) 84 (87%) 203 (83%) 0.067
Incident HSV2
infection
2 (1%) 2 (2%) 5(2%)
HSV2 negative 53 (23%) 11 (11%) 37 (17%)
HSV2 serology of HIV positive partner HSV2 positive at
enrollment
197 (84%) 91 (92%) 222 (91%) 0.050
Incident HSV2
infection
2 (1%) 1 (1%) 0 (0)
HSV2 negative 35 (15%) 7 (7%) 23 (9%)
Any bacterial vaginoisis during study 44 (19%) 17 (17%) 39 (16%) 0.709
Any bacterial vaginoisis among HIV negatives during
the study
17 (14%) 8 (13%) 22 (15%) 0.962
Use Other Family Planning (HIV positive partner’s
response)
29 (12%) 12 (13%) 25 (10%) 0.711
Use injectable contraception (female response) 144 (61%) 67 (68%) 163 (66%) 0.371
*Three of the seroconverter couples did not have VL results prior to seroconversion, for two of these couples we used the most recent VL result which
occurred after seroconversion
doi:10.1371/journal.pone.0132182.t002
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VL prior to seroconversion was<1000 copies/ mL. Four participants seroconverted after their
partner’s most recent viral load was<20 copies/ mL; two of these were genetically linked, one
was unlinked and one did not have linkage data available. In one of the nine seroconverting
participants from ART couples, we found evidence of transmitted drug resistance but no evi-
dence of resistance mutations in the viruses of their HIV positive partner. This is most likely
due to the fact that the latter samples came from pro-viral DNA samples and not from plasma.
The bivariate analysis of factors associated with seroconversion is shown in Table 4. Partici-
pants who were in polygynous relationships (47% vs. 24%; p = 0.042); couples where the female
participant reported an early age of sexual debut (median age 15 years vs. 16 years; p = 0.018)
and couples where the male participant reported that he decides when they have sex (59% vs.
35%; p = 0.044) were associated with seroconversion during the study. No association was
found with HSV2 seropositivity during the study and HIV seroconversion. Having a VL>1000
copies/ mL was also associated with seroconversion (69% vs. 35%; p = 0.006). However, ART-
use for greater than three months was not associated (p = 0.550). A larger proportion of
women were the HIV negative participant in the couples where seroconversion occurred (13/
17 [76%] vs. 293/527 [56%]). However, this was not statistically significant (p = 0.088).
Fig 1. Study profile of the Highly Active Antiretroviral therapy as Prevention (HAARP) Study.
doi:10.1371/journal.pone.0132182.g001
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Table 4. Bivariate Analysis comparing 17 discordant couples where seroconversion occurred with 527 discordant couples where no seroconver-
sion occurred.
Seroconverters
(n = 17)
Non seroconverters
(n = 527)
P- value
ART status (%) Never on ART 4 (24%) 206 (39%) 0.145
Began ART during the
study
6 (35%) 93 (18%)
On ART at enrollment 7 (41%) 228 (43%)
ART status (%) On ART at least 3
months
9 (53%) 317 (60%) 0.550
Not on ART or on ART
3 months
8 (47%) 210 (40%)
Sex of HIV negative participant (%) Female 13 (76%) 293 (56%) 0.088
Male 4 (24%) 234 (44%)
Intergenerational relationship (>10 yrs age difference
between male and female partner) (%)
7 (41%) 183 (35%) 0.583
Primary Language Spoken (male response) (%) Lusoga 12 (71%) 335 (65%) 0.645
Other 5 (29%) 179 (35%)
Polygyneous partnership (%) 8 (47%) 126 (24%) 0.042
Male partner circumcised (%) 4 (24%) 210 (40%) 0.163
Used a condom at last sex (positive partner) (%) 13 (76%) 374 (71%) 0.789
Used a condom at last sex (negative partner) (%) 13 (76%) 388 (74%) 1.000
Condom use in the last 3 months (male) (%) Always 12 (71%) 337 (64%) 0.937
Sometimes 3 (18%) 101 (19%)
Never 2 (12%) 89 (17%)
Age of sexual debut (male) Median (IQR) 19 (15–23) 18 (16–20) 0.314
Age of sexual debut (female) Median (IQR) 15 (14–16) 16 (15–18) 0.018
# of lifetime sex partners (male) Median (IQR) 4 (4–10) 6 (4–12) 0.261
# of lifetime sex partners (female) Median (IQR) 4 (3–7) 3(2–4) 0.085
Male sexual decision making (male response) (%) 10 (59%) 184 (35%) 0.044
Duration of relationship with primary partner (in years)
Median (IQR)
7.8 (4.5–12.5) 11.6 (5.8–20.2) 0.163
Number of sexual partners for non-polygynous males (%) More than one 0 (0%) 22 (5%) 1.000
One 9 (100%) 379 (95%)
>1 sexual partner reported by female 0 8 (2%) 1.000
Intend to have more children (male response) 5 (42%) 172 (36%) 0.765
Intend to have more children (female response) 6 (40%) 103 (24%) 0.220
Median VL (log 10 copies/ mL) at study exit or prior to sero-
conversion
4.8 (1.8–5.15) 1.5 (1.3–4.2) 0.006
VL >1000 copies/ mLat study exit or prior to sero-
conversion (n and %)
11/16 (69%) 168/475 (35%) 0.006
CD4 cell count at enrollment of HIV positive partner Median
(IQR)
329 (162–422) 419 (274–592) 0.079
HSV2 serology at enrollment of HIV negative partner (n and
%)
HSV2 positive 13 (93%) 425 (81%) 0.592
HSV2 negative 1 (7%) 108 (19%)
HSV2 serology at enrollment of HIV positive partner (n and
%)
HSV2 positive 14 (88%) 460 (88%) 0.725
HSV2 negative 2 (13%) 61 (12%)
Any genital ulcer disease reported by HIV positive 1 (6%) 9 (2%) 0.276
Any genital ulcer disease reported by HIV negative 0 (0%) 3 (1%) 1.000
Any bacterial vaginosis during study 2 (12%) 92 (17%) 0.750
Any bacterial vaginosis among HIV negatives during the
study
1 (8%) 44 (15%) 0.700
(Continued)
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Univariate Cox proportional hazards modeling found that no association with time-updated
ART use (hazard ratio [HR] 1.07; 95% confidence interval [CI] 0.41–2.80). Similarly none of
our stratified Cox analyese demonstrated associations between ART use and seroconversion.
The HR for ART-use when stratified by male circumcision status was 1.01 (95% CI 0.39–2.67);
when stratified by HSV2 serostatus of the HIV positive participant it was 0.94 (95% CI 0.35–
2.55); when stratified by the HSV2 serostatus of the HIV negative participant it was 0.90 (95%
CI 0.31–2.60); when stratified by the gender of the HIV positive participant it was 1.02 (95% CI
0.39–2.68) and when stratified by the CD4 cell count nadir of the HIV positive200 cells/μL,
it was 0.581 (95% CI 0.10–3.27).
Discussion
In this study, ART use by the HIV positive partner was not associated with a reduced risk of
HIV transmission among HIV serodiscordant couples. This result contrasts with many previ-
ous clinical studies of ART as prevention that have found effectiveness varying from 26%- 96%
[4, 15–19], as well as several ecologic studies[2, 3]. Both the median log10 VL and the propor-
tion of participants with VLs>1000 copies/ mL were significantly higher among the HIV posi-
tive partners in the seroconverting couples, but this did not directly correlate with a reduced
risk of transmission from the ART couples. Participants in polygyneous relationships and
where the male partner made sexual decisions for the couple were more likely to seroconvert
during our study, as were couples where the female participant reported an early age of sexual
debut.
The HPTN 052 study found a 96% reduction in HIV transmission associated with the early
use of ART among 1763 serodiscordant couples [4]. However, the estimate of effectiveness was
reduced to 75% if non-genetically linked transmissions were included. Another observational
study from multiple sites in Eastern and Southern Africa found a similar 92% reduction in
transmission risk associated with ART use[15]. However, the context of ART-use in our study
was quite different than in these, in that most participants who were receiving ART had done
so for more than two years before study enrollment and they did not have access to VL testing.
Nevertheless, virologic control among the HIV-infected participants was very good in that
only 7% of the individuals who were receiving ART at initiation and 23% of individuals who
initiated ART during the study had a VL measurement>1000 copies/ mL, so that large num-
bers of ART patients with undiagnosed treatment failure cannot provide an explanation for
these results. A Cochrane review examining the published literature on ART for prevention of
HIV transmission among serodiscordant couples, found an overall incidence rate ratio of 0.34
(95% CI 0.13–0.92) among seven previously published observational studies with substantial
heterogeneity between studies[20]. When the analysis was restricted to only studies from low-
income countries a similar incidence rate ratio was noted (0.27), but the result was only
Table 4. (Continued)
Seroconverters
(n = 17)
Non seroconverters
(n = 527)
P- value
Use Other Family Planning (HIV positive partner’s
response)
0 61 (12%) 0.240
Use injectable contraception (female response) 12 (71%) 339 (64%) 0.602
*Three of the seroconverter couples did not have VL results prior to seroconversion, for two of these couples we used the most recent VL result which
occurred after seroconversions
doi:10.1371/journal.pone.0132182.t004
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marginally statistically significant (p = 0.06). The authors noted that the quality of the evidence
was low for this sub-analysis, an area to which our current study may now contribute.
The relatively low rate of HIV incidence in the non-ART couples (2.30 per 100 PYRs) may
be due to the high prevalence of condom-use in this cohort, but may more accurately reflect
the background HIV transmission risk of serodiscordant couples where the positive partner is
already engaged in HIV care and receiving prevention counselling. In the systematic review,
above, the median incidence rate for this group was 7.5 per 100 PYRs[20]. Reported condom-
use at last sex in our study was over 70% at enrollment and increased to over 90% by one year
of follow-up[21]. In fact, it appears from our sub-analysis of couples where the HIV positive
participant began ART during the study, that ART-use may have prevented some HIV trans-
mission events, since the incidence rate for the individuals starting treatment was much higher
(4.54 per 100 PYRs) than in the period immediately following treatment initiation (2.56 per
100 PYRs), although these differences were not statistically significant. The overall transmis-
sion rate of 2.03 per 100 PYRs among the partners of HIV infected participants who were
receiving ART at any point during our study approximates the mid-point estimate (2.5 per 100
PYRs) derived from systematic review[20]. Our findings suggest that efforts to promote the
widespread adoption of other HIV prevention strategies, such as condom promotion, couples
counselling and testing, partner reduction and medical male circumcision, should continue in
parallel with the ongoing expansion of ART.
It is possible that the higher proportion of uncircumcised men and HSV2 seroprevalence in
the couples where ART was used may have diminished the effectiveness of ART in preventing
transmission. However, these differences in distribution were quite small (9% for circumcision,
8% for HSV2 prevalence among HIV positives) and seem unlikely to completely counteract the
expected efficacy of ART in preventing HIV transmission. Furthermore, we did not find any
effect on ART-use by the HIV positive partner in analyses stratified on the basis of circumci-
sion status, gender or HSV2 seroprevalence. Nevertheless, we cannot rule out interactions in
the differences between these important co-factors of HIV transmission. However, it is also
worth noting that some of the differences in variables known to be associated with HIV trans-
mission, such as condom-use and relationship duration, would have biased our study towards
having a reduced risk of HIV transmission among the ART couples, irrespective of the effect of
ART. Such factors have been previously identified as biases in observational studies examining
this issue[22].
Our study has a number of limitations. Firstly, our study was underpowered to detect the
moderately sized decreases in HIV transmission (75%) associated with ART-use because the
incidence in the couples where the positive partner did not receive treatment was lower than we
had anticipated. However, a post-hoc power calculation did find that we had sufficient statistical
power to detect a 95% reduction in transmission associated with ART-use. Our study, however,
cannot rule out an effect of ART which was less than this. Secondly, the VL measurements we
obtained could have been taken up to six months prior to the date of seroconversion and there-
fore may have missed episodes of high viremia which may have caused transmission. The small
number of transmission events also meant that we were unable to adjust our analyses to control
for all potential confounders. Finally, as with all observational studies, confounding by other fac-
tors which we did not measure may also have contributed to the lack of effect we observed.
In summary, we did not demonstrate a benefit of the use of ART in preventing HIV trans-
mission among serodiscordant couples in Uganda. A possible explanation for this observation
is that couples were already using condoms and had participated in some risk reduction
counseling, thus limiting the possibility to show further benefits from ART. Our results high-
light the need for conducting operational research in similar program settings to determine the
real-world impact of interventions which have been proven in clinical trials.
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